Stock Performance and Market Context
Epigral Ltd’s share price has been on a declining trajectory, falling by 1.18% today and underperforming its sector by 1.4%. This marks the third consecutive day of losses, with the stock delivering a negative return of 5.43% over this period. The current price of Rs.1263.1 is substantially lower than its 52-week high of Rs.2114.3, representing a decline of nearly 40.3% from that peak.
The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a persistent bearish momentum. This contrasts with the broader market, where the Sensex opened flat but is currently trading marginally lower at 84,918.54, down 0.14%. Notably, the Sensex remains close to its 52-week high of 86,159.02, just 1.46% away, and is supported by bullish moving averages with the 50-day DMA above the 200-day DMA.
Financial Performance Highlights
Epigral Ltd’s financial results have contributed to the subdued market sentiment. The company reported a Profit Before Tax (PBT) excluding other income of Rs.67.91 crores in the September 2025 quarter, which represents a sharp decline of 45.2% compared to the average of the previous four quarters. Similarly, Profit After Tax (PAT) for the quarter stood at Rs.51.22 crores, down 52.6% relative to the prior four-quarter average.
Interest expenses have increased significantly, with a 37.3% rise over the nine-month period, reaching Rs.56.98 crores. This increase in interest cost has likely weighed on profitability and cash flow metrics.
Over the last five years, the company’s operating profit has contracted at an annualised rate of 5.49%, indicating challenges in sustaining long-term growth momentum. This has been reflected in the stock’s performance, which has delivered a negative return of 32.65% over the past year, markedly underperforming the Sensex’s positive 7.87% return during the same period.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Valuation and Efficiency Metrics
Despite the recent price weakness, Epigral Ltd exhibits some positive financial characteristics. The company maintains a high Return on Capital Employed (ROCE) of 23.19%, indicating efficient utilisation of capital in generating profits. Additionally, the Debt to EBITDA ratio stands at a manageable 1.34 times, reflecting a strong capacity to service debt obligations.
The valuation metrics also suggest the stock is trading at a discount relative to its peers. With a ROCE of 19.3% and an Enterprise Value to Capital Employed ratio of 2.3, the company’s shares appear attractively valued on a relative basis. Over the past year, while the stock price has declined by 32.8%, the company’s profits have increased by 37.1%, resulting in a low PEG ratio of 0.4, which typically indicates undervaluation when considered alongside earnings growth.
Long-Term and Recent Relative Performance
Epigral Ltd’s stock has underperformed not only the Sensex but also the BSE500 index over multiple time horizons, including the last three years, one year, and three months. This underperformance highlights the challenges faced by the company in delivering shareholder returns relative to broader market benchmarks and sector peers.
The majority shareholding remains with the promoters, which may provide some stability in ownership structure amid the current price volatility.
Why settle for Epigral Ltd? SwitchER evaluates this Specialty Chemicals small-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Mojo Score and Ratings
Epigral Ltd currently holds a Mojo Score of 31.0, with a Mojo Grade of Sell as of 26 December 2025, an upgrade from its previous Strong Sell rating. The Market Cap Grade is rated at 3, reflecting moderate market capitalisation relative to other stocks in the sector. These ratings encapsulate the company’s recent financial performance and market positioning.
Summary of Key Data Points
To summarise, Epigral Ltd’s stock has reached a new 52-week low of Rs.1263.1, reflecting a sustained decline over recent months. The company’s financial results show significant reductions in quarterly profits and rising interest expenses, while long-term growth rates remain subdued. Despite these challenges, the firm maintains strong capital efficiency and manageable debt levels, with valuation metrics indicating a discount relative to peers.
The broader market environment remains relatively stable, with the Sensex near its 52-week high and supported by bullish moving averages, contrasting with Epigral’s weaker price action and underperformance.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today
